Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1

A family of drug transporters: the multidrug resistance-associated proteins

Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

Schuetz, J. D., Connelly, M., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V., Kumar, A., & Fridland, A. (1999) · Nature Medicine · doi:10.1038/12487 · Cited by 575

Multidrug resistance: molecular mechanisms and clinical relevance

Ling, V. W. T. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051053 · Cited by 525

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439

Structural, mechanistic and clinical aspects of MRP1

Hipfner, D. R., Deeley, R. G., & Cole, S. P. C. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00168-6 · Cited by 412

A comparison of the biological activities of wild‐type and mutant p53

Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 410

p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.

Fan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 404

Multiple physiological functions for multidrug transporter P-glycoprotein?

Johnstone, R. W., Ruefli, A. A., & Smyth, M. J. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01493-0 · Cited by 308

Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

Duffy, M. J., Tang, M., Rajaram, S., O’Grady, S., & Crown, J. P. (2022) · Cancers · doi:10.3390/cancers14184499 · Cited by 49

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

Musacchio, L., Caruso, G., Pisano, C., Cecere, S. C., Napoli, M. D., Attademo, L., Tambaro, R., Russo, D., Califano, D., Palaia, I., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s221001 · Cited by 48

Transcriptional suppression of breast cancer resistance protein (BCRP) by wild‐type p53 through the NF‐κB pathway in MCF‐7 cells

Wang, X., Wu, X., Wang, C., Zhang, W., Ouyang, Y., Yu, Y., & He, Z. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.033 · Cited by 47

Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression

Valenti, F., Ganci, F., Fontemaggi, G., Sacconi, A., Strano, S., Blandino, G., & Agostino, S. D. (2015) · Oncotarget · doi:10.18632/oncotarget.2587 · Cited by 45

Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines.

Breen, L., Heenan, M., Murphy, V., & CLYNES, M. M. (2007) · PubMed · Cited by 44

MicroRNAs as Key Effectors in the p53 Network

Goeman, F., Strano, S., & Blandino, G. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.04.003 · Cited by 44

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches

Roszkowska, K. A., Piecuch, A., Sady, M., Gajewski, Z., & Flis, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113287 · Cited by 48

p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines

Ye, S., Shen, J. K., Choy, E., Cao, Y., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2944-z · Cited by 43

Sensitization of Chemo-Resistant Human Chronic Myeloid Leukemia Stem-Like Cells to Hsp90 Inhibitor by SIRT1 Inhibition

Kim, H.-B., Lee, S.-H., Um, J., Kim, M., Hyun, S.-K., Gong, E. J., Oh, W. K., Kang, C., & Kim, S. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10896 · Cited by 42

Interactions of mutant p53 with DNA: guilt by association

Kim, E. L., & Deppert, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210312 · Cited by 46

Direct regulation of BCL‐2 by FLI‐1 is involved in the survival of FLI‐1‐transformed erythroblasts

Lesault, I., Quang, C. T., Frampton, J., & Ghysdael, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.694 · Cited by 45

Awakening the “guardian of genome”: reactivation of mutant p53

Binayke, A., Mishra, S., Suman, P., Das, S., & Chander, H. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3701-x · Cited by 40

MYCN Enhances P-gp/MDR1 Gene Expression in the Human Metastatic Neuroblastoma IGR-N-91 Model

Blanc, É., Goldschneider, D., Ferrandis, E., Barrois, M., Roux, G. L., Léonce, S., Douc‐Rasy, S., Bénard, J., & Raguénez, G. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63656-5 · Cited by 41

Ets1 Induces Dysplastic Changes When Expressed in Terminally-Differentiating Squamous Epidermal Cells

Nagarajan, P., Parikh, N., Garrett‐Sinha, L. A., & Sinha, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004179 · Cited by 40

Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance

Sankala, H. M., Vaughan, C. A., Wang, J., Deb, S., & Graves, P. R. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.05.005 · Cited by 40

Modulation of heme and myristate binding to human serum albumin by anti‐HIV drugs

Fanali, G., Bocedi, A., Ascenzi, P., & Fasano, M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05978.x · Cited by 40

Drug resistant breast cancer cells overexpress ETS1 gene

Kars, M. D., İşeri, Ö. D., & Gündüz, U. (2010) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2010.01.008 · Cited by 40

The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction

Vodicka, P., Andera, L., Opattova, A., & Vodickova, L. (2021) · Cancers · doi:10.3390/cancers13030479 · Cited by 39

p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act

Guo, Y., Tang, Y., Lu, G., & Gu, J. (2023) · Nutrients · doi:10.3390/nu15102259 · Cited by 40

Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells

Khanna, A., Mahalingam, K., Chakrabarti, D., & Periyasamy, G. (2011) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-010-0043-z · Cited by 39

Functions of TAp63 and p53 in restraining the development of metastatic cancer

Tan, E. H., Morton, J. P., Timpson, P., Tucci, P., Melino, G., Flores, E. R., Sansom, O. J., Vousden, K. H., & Muller, P. A. J. (2013) · Oncogene · doi:10.1038/onc.2013.287 · Cited by 39

Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition

You, D., Richardson, J. R., & Aleksunes, L. M. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089953 · Cited by 40

Mechanistic studies of S-nitrosothiol formation by NO/O2 and by NO/methemoglobin

Herold, S., & Röck, G. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.02.013 · Cited by 38

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer

Alzoubi, S., Brody, L., Rahman, S., Mahul-Mellier, A.-L., Mercado, N., Ito, K., El-Bahrawy, M., Silver, A., Boobis, A., Bell, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9887 · Cited by 37

Allosteric modulation of monomeric proteins*

Ascenzi, P., Bocedi, A., Bolli, A., Fasano, M., Notari, S., & Polticelli, F. (2005) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.2005.494033032470 · Cited by 37

Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?

Lim, D. V., Woo, W. H., Lim, J. X., Loh, X. Y., Soh, H. T., Lim, S. Y. A., Lee, Z. Y., Yow, H.-Y., Hamzah, S. B., Sellappans, R., et al. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230914090621 · Cited by 36

Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response

Литвяков, Н. В., Чердынцева, Н. В., Tsyganov, M. M., Denisov, E. V., Garbukov, Е. Y., Мерзлякова, М. К., Волкоморов, В. В., Vtorushin, S. V., Zavyalova, M. V., Slonimskaya, E. M., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1992-x · Cited by 36

p53: Its Mutations and Their Impact on Transcription

Vaughan, C. A., Pearsall, I., Yeudall, W. A., Deb, S. P., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_4 · Cited by 37

A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53mut exhibits ATP-binding cassette transporter upregulation and high glutathione levels

Tonigold, M., Rossmann, A., Meinold, M., Bette, M., Maerken, M., Henkenius, K., Bretz, A. C., Giel, G., Cai, C., Rodepeter, F. R., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1727-y · Cited by 35

Battle Against Cancer: An Everlasting Saga of p53

Hao, Q., & Cho, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151222109 · Cited by 38

Taxane Refractory Prostate Cancer

Mathew, P. F., & DiPaola, R. S. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.04.032 · Cited by 35

Mutant p53 Protects Cells from 12- O -Tetradecanoylphorbol-13-Acetate–Induced Death by Attenuating Activating Transcription Factor 3 Induction

Buganim, Y., Kalo, E., Brosh, R., Besserglick, H., Nachmany, I., Rais, Y., Stambolsky, P., Tang, X., Milyavsky, M., Shats, I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0916 · Cited by 34

Recognition of Local DNA Structures by p53 Protein

Brázda, V., & Coufal, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020375 · Cited by 41

ABCB1 and GST polymorphisms associated with TP53 status in breast cancer

Nord, S., Ritchie, M. D., Jensrud, S. D., Motsinger‐Reif, A. A., Alnæs, G. I. G., Lemmon, G., Berg, M., Geisler, S. B., Moore, J. H., Lønning, P. E., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328011abaa · Cited by 34

Deciphering the significance of p53 mutant proteins

Butera, A., & Amelio, I. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.06.003 · Cited by 36

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma

Jin, L., Tabe, Y., Kimura, S. H., Zhou, Y.-K., Kuroda, J., Asou, H., Inaba, T., Konopleva, M. Y., Andreeff, M., & Miida, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606007 · Cited by 33

p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis

Lv, T., Wu, X., Sun, L., Hu, Q., Wan, Y., Wang, L., Zhao, Z., Tu, X., & Xiao, Z. J. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.376 · Cited by 33

Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

Fedorova, O., Daks, A. A., Shuvalov, O. Y., Kizenko, A., Petukhov, A., Gnennaya, Y., & Barlev, N. A. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00337-4 · Cited by 37

Regulation of the Mdr1 isoforms in a p53-deficient mouse model

Bush, J. (2002) · Carcinogenesis · doi:10.1093/carcin/23.10.1603 · Cited by 32

Dioxomorpholines and Derivatives from a Marine-Facultative Aspergillus Species

Aparicio-Cuevas, M. A., Rivero‐Cruz, I., Sánchez‐Castellanos, M., Menéndez, D., Raja, H. A., Joseph‐Nathan, P., González, M. D. C., & Figueroa, M. (2017) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00331 · Cited by 31

TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1- NF-κB and - AP-1 pathways

Zhao, P., Wang, S., Jiang, J., Liu, H., Zhu, X., Zhao, N., Li, J., Yin, Y., Pan, X., Yang, X., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.08.010 · Cited by 30

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter

Vaughan, C. A., Pearsall, I., Singh, S., Windle, B. E., Deb, S. P., Grossman, S. R., Yeudall, W. A., & Deb, S. (2016) · Oncotarget · doi:10.18632/oncotarget.6998 · Cited by 29

Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1

Kim, H.-B., Lee, S.-H., Um, J., Oh, W. K., Kim, D.-W., Kang, C., & Kim, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5343 · Cited by 29

Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin

Qi, X., Zhi-kun, C., Song, J. P., Gao, G., & Shen, Z. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328345b4e7 · Cited by 28

Complexes formed by mutant p53 and their roles in breast cancer

Bellazzo, A., Sicari, D., Valentino, E., Sal, G. D., & Collavin, L. (2018) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s145826 · Cited by 28

A Novel p53 Phosphorylation Site within the MDM2 Ubiquitination Signal

Fraser, J. A., Madhumalar, A., Blackburn, E. A., Bramham, J., Walkinshaw, M. D., Verma, C. S., & Hupp, T. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.143107 · Cited by 29

Combined dual effect of modulation of human neutrophils’ oxidative burst and inhibition of colon cancer cells proliferation by hydroxycinnamic acid derivatives

da Silva, E. J. T., Varela, C. L., Pires, A. S., Encarnação, J. C., Abrantes, A. M., Botelho, M. F., Carvalho, R. A., Proença, C., Freitas, M., Fernandes, E. G. R., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.065 · Cited by 28

Repeated dosing of piperine induced gene expression of P‐glycoprotein via stimulated pregnane‐X‐receptor activity and altered pharmacokinetics of diltiazem in rats

Fu, Q., Kang, K. W., & Han, H. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1811 · Cited by 27

Asparagine Dependency Is a Targetable Metabolic Vulnerability in TP53 -Altered Castration-Resistant Prostate Cancer

Yoo, Y. A., Quan, S., Yang, W., Guo, Q., Rodríguez, Y., Chalmers, Z. R., Dufficy, M. F., Lackie, B., Sagar, V., Unno, K., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2910 · Cited by 26

Mutant p53 and ETS2, a Tale of Reciprocity

Martinez, L. A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00035 · Cited by 26

Transcriptional Regulation by Mutant p53 and Oncogenesis

Santoro, R., Strano, S., & Blandino, G. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_5 · Cited by 25

Transcriptional and signalling regulation of skin epithelial stem cells in homeostasis, wounds and cancer

Guan, Y., Yang, Y. J., Nagarajan, P., & Ge, Y. (2020) · Experimental Dermatology · doi:10.1111/exd.14247 · Cited by 27

GOF Mutant p53 in Cancers: A Therapeutic Challenge

Dolma, L., & Muller, P. A. J. (2022) · Cancers · doi:10.3390/cancers14205091 · Cited by 29

Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane

Phatak, V. M., von Grabowiecki, Y., Janus, J., Officer-Jones, L., Behan, C., Aschauer, L., Piñon, L., Mackay, H. L., Zanivan, S. R., Norman, J. C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03497-y · Cited by 24

A Brief Review on Chemoresistance; Targeting Cancer Stem Cells as an Alternative Approach

Toledo, B., González-Titos, A., Hernández-Camarero, P., & Perán, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054487 · Cited by 26

Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death

Choe, J. H., Kawase, T., Xu, A., Guzman, A., Obradović, A., Low-Calle, A. M., Alaghebandan, B., Raghavan, A., Long, K., Hwang, P. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0882 · Cited by 25

Ets1 is an effector of protein kinase Cα in cancer cells

Vetter, M., Blumenthal, S. G., Lindemann, R. K., Manns, J., Wesselborg, S., Thomssen, C., & Dittmer, J. (2004) · Oncogene · doi:10.1038/sj.onc.1208234 · Cited by 24

Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis

Yue, X., Wu, F., Li, Y., Liu, J., Boateng, M. N., Mandava, K., Zhang, C., Feng, Z., Gao, J., & Hu, W. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1749790 · Cited by 23

Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences

Lazarowski, A., Czornyj, L., Lubieniecki, F. J., Vázquez, S., D’Giano, C., Sevlever, G. E., Taratuto, A. L., Brusco, A., & Girardi, E. (2006) · Current Drug Therapy · doi:10.2174/157488506778194910 · Cited by 25

Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription

Oh, S., Lee, K. W., Madhi, H., Jeong, J.-W., Park, S., Kim, M.-J., Lee, Y., Han, H.-T., Hwangbo, C., Yoo, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051710 · Cited by 23

Mechanisms and therapeutic potential of inhibiting drug efflux transporters

Klukovits, A., & Krajcsi, P. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1028917 · Cited by 23

Inducing cancer cell death by targeting transcription factors

Kim, R., Tanabe, K., Emi, M., Uchida, Y., Inoue, H., & Toge, T. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200301000-00002 · Cited by 23

Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date

Hwang, S. H., Baek, S. H., Lee, M. J., Kook, Y., Bae, S. J., Ahn, S. G., & Jeong, J. (2024) · Cancers · doi:10.3390/cancers16233899 · Cited by 21

Noncanonical roles of p53 in cancer stemness and their implications in sarcomas

Curylova, L., Ramos, H., Saraiva, L., & Skoda, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.037 · Cited by 21

Oncogenomic Approaches in Exploring Gain of Function of Mutant p53

Donzelli, S., Biagioni, F., Fausti, F., Strano, S., Fontemaggi, G., & Blandino, G. (2008) · Current Genomics · doi:10.2174/138920208784340713 · Cited by 22

The p53 Tumor Suppressor Pathway and Cancer

Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 20

microRNAs: short non-coding bullets of gain of function mutant p53 proteins

Donzelli, S., Strano, S., & Blandino, G. (2014) · Oncoscience · doi:10.18632/oncoscience.52 · Cited by 19

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22

Control of Nucleotide Metabolism Enables Mutant p53’s Oncogenic Gain-of-Function Activity

Schmidt, V. A., Nagar, R., & Martinez, L. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122759 · Cited by 20

Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.

Adhikari, A. S., & Iwakuma, T. (2009) · PubMed · doi:10.15017/15090 · Cited by 18

Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes

Joshi, H. N., Nord, S., Frigessi, A., Børresen‐Dale, A., & Kristensen, V. N. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-199 · Cited by 18

Multidrug Resistance Proteins in Renal Cell Carcinoma

Hodorová, I., Rybárová, S., Solár, P., Vecanová, J., Mihálik, J., Bohus, P., Mellová, Y., & Kluchová, D. (2008) · Folia Biologica · doi:10.14712/fb2008054060187 · Cited by 18

Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites

Vaughan, C. A., Deb, S. P., Deb, S., & Windle, B. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1708 · Cited by 17

Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1

Wei, J., Zhou, Y., Jiang, G., & Xiao, D. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-22 · Cited by 17

Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death

Moon, H., Kim, H.-B., Lee, S.-H., Jeun, S. E., Kang, C., & Kim, S. (2018) · Oncotarget · doi:10.18632/oncotarget.24130 · Cited by 16

Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells

Shang-Hsun, T., Hou, M.-H., Hsu, L., Chen, T.-M., & Chen, Y. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2406 · Cited by 15

TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell

Lei, G., Liu, S., Yang, X. L., & He, C. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8870907 · Cited by 14

Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion

Kadioglu, O., Saeed, M. E. M., Mahmoud, N., Azawi, S. S. H., Mrasek, K., Liehr, T., & Efferth, T. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-02979-4 · Cited by 14

TIPE1 Promotes Cervical Cancer Cell Chemoresistance to Cisplatin in a Wild-Type p53-Dependent Manner

Jiang, J., Gao, L., Lan, Y., Wang, Y., & Zhao, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.593615 · Cited by 12

Efflux transporters in cancer resistance: Molecular and functional characterization of P-glycoprotein

Turner, A. P., Alam, C., & Bendayan, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816434-1.00001-2 · Cited by 13

Multidrug Resistance Mediated by MDR-ABC Transporters

Szakács, G., Wah, K. K., Polgár, O., Robey, R. W., & Bates, S. E. (2009) · Springer eBooks · doi:10.1007/978-0-387-89445-4_1 · Cited by 12

Mutant p53: evolving perspectivesPreprint

Efe, G., Cunningham, K. M., Rustgi, A. K., Prives, C. L., Manfredi, J. J., & Rivera, F. J. S. (2025) · Genes & Development · doi:10.1101/gad.353408.125 · Cited by 16

Transcriptional repression of Aurora‐A gene by wild‐type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a

Yang, T., Teng, C. J., Lin, T., Chen, K., Hsu, S., & Wu, C. (2017) · International Journal of Cancer · doi:10.1002/ijc.31035 · Cited by 11

FTIR investigation of the conformational properties of the cyanide bound human hemoglobin

Al-Mustafa, J. I. (2002) · Vibrational Spectroscopy · doi:10.1016/s0924-2031(02)00008-5 · Cited by 11

Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma

Zhang, Z., Deng, X., Ren, X., Zhang, B., Chen, X., Yang, J., Ding, H., Sui, J., & Song, X. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521003734117 · Cited by 10

Quantitative Analysis of Multidrug‐resistance mdr1 Gene Expression in Head and Neck Cancer by Real‐time RT‐PCR

Tseng, C., Cheng, A., Chang, J. T., Tseng, C., Wang, H., Liao, C., Chen, I.-H., & Tseng, K. C. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01228.x · Cited by 10

Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin

Poma, P., Rigogliuso, S., Labbozzetta, M., Nicosia, A., Costa, S., Ragusa, M. A., & Notarbartolo, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413416 · Cited by 9

Targeted Chemotherapy in Drug-Resistant Tumors, Noninvasive Imaging of P-Glycoprotein-Mediated Functional Transport in Cancer, and Emerging Role of Pgp in Neurodegenerative Diseases

Sivapackiam, J., Gammon, S. T., Harpstrite, S. E., & Sharma, V. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_8 · Cited by 9

p53: Balancing tumour suppression and implications for the clinic

Buganim, Y., & Rotter, V. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70037-1 · Cited by 9

An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53

Foroutan, B., Ruf, A. A., Costall, B., & Anderson, D. C. (2006) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2006.05.008 · Cited by 9

Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells

Mehta, H., Ambele, M. A., Mokgautsi, N., & Moela, P. (2024) · Cells · doi:10.3390/cells13080700 · Cited by 8

Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63

Ogata, T., Nakamura, M., Sang, M., Yoda, H., Hiraoka, K., Yin, D., Sang, M., Shimozato, O., & Ozaki, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179884 · Cited by 8

Dual roles of TRIM3 in colorectal cancer by retaining p53 in the cytoplasm to decrease its nuclear expression

Han, Y., Lu, S., Song, C., Xuan, Y., Zhang, M., & Cai, H. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01386-1 · Cited by 7

Relation between expression pattern of wild-type p53 and multidrug resistance proteins in human nephroblastomas

Hodorová, I., Rybárová, S., Vecanová, J., Solár, P., Plank, L., & Mihálik, J. (2012) · Acta Histochemica · doi:10.1016/j.acthis.2012.08.001 · Cited by 7

Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells

Zhang, Y., Wang, C., Wang, Z.-G., Ma, D., Pan, S., Zhu, S., Li, F., & Wang, B. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9431-2 · Cited by 7

Coexpression of Ets-1 and p53 in oral carcinomas is associated with P-glycoprotein expression and poor prognosis

Soni, S., Pande, P. K., Shukla, N. K., & Ralhan, R. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0345-2 · Cited by 7

Role of E ts‐1 in fibronectin‐derived heparin‐binding domain polypeptides alleviating melanoma cell invasiveness and chemoresistance

Tang, N., Wang, X., Huang, T., Wu, Y., & Chen, Y. (2014) · Experimental Dermatology · doi:10.1111/exd.12444 · Cited by 6

Comparison of Effects of p53 Null and Gain-of-Function Mutations on Salivary Tumors in MMTV-Hras Transgenic Mice

Jiang, D., Dumur, C. I., Massey, H. D., Ramakrishnan, V., Subler, M. A., & Windle, J. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118029 · Cited by 5

Advances on mutant p53 research

Li, D. (2008) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2008.00697 · Cited by 6

Cell type‐specific regulation of calmodulin 2 expression by mutant p53

Knaup, K. X., & Roemer, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.05.052 · Cited by 6

The Region 3′ to the Major Transcriptional Start Site of the MDR1 Downstream Promoter Mediates Activation by a Subset of Mutant P53 Proteins

Strauss, B. E., & Haas, M. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2781 · Cited by 33

Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants.

Nguyen, K. T., Liu, B.-Y., Ueda, K., Gottesman, M. M., Pastan, I. H., & Chin, K. (1994) · PubMed · Cited by 54

Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells

Nicoletti, M. I., Myers, T. G., Fojo, T., & Blagosklonny, M. V. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.2.375 · Cited by 5

Mutant p53 cooperates with ETS2 to promote etoposide resistancePreprint

Do, P. M., Varanasi, L., Fan, S., Li, C., Kubacka, I., Newman, V., Chauhan, K. M., Daniels, S. R., Boccetta, M., Garrett, M. R., et al. (2012) · Genes & Development · doi:10.1101/gad.181685.111 · Cited by 201

Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.

Wang, Q., & Beck, W. T. (1998) · PubMed · Cited by 112